Showing all posts written by Jane Xia

Jane Xia
Jane Xia
Jane Xia's practice involves patent procurement, intellectual property due diligence, Patent Office appeals, intellectual property strategy counseling, and worldwide patent portfolio management. Jane represents clients in a wide range of technologies, including pharmaceuticals, nutraceuticals, semiconductor fabrication, battery technology, life sciences, polymer sciences, medical devices, diagnostic devices, cosmetic and personal care products.
She has experience representing individual inventors, venture funded start-ups, university spin-offs, and publicly traded companies. She also represents a number of foreign clients in procuring U.S. patent protection in the Pharmaceutical and semiconductor technologies. Before attending law school, she worked as a research scientist in nanomaterials production and gained industry experience in developing quantum dots and nanomaterials in display technology.
Jane worked as a summer associate at the firm in 2011 and joined the firm in 2012.

Improper Markush Rejection: The New Kid on the Patent Block

The U.S. Patent and Trademark Office (“USPTO”) quietly increased the examiners’ arsenal by slipping a new rejection into the latest revision of the Manual of Patent Examining Procedure (“MPEP”) released last month. One of the